Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | The value of MRD assessment in CLL

Arnon Kater • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia
MURANO

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, explains the value of measurable residual disease (MRD) assessment for chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals